Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE

Bank of America Corp DE grew its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 59.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 127,159 shares of the company's stock after acquiring an additional 47,439 shares during the quarter. Bank of America Corp DE owned 0.28% of Y-mAbs Therapeutics worth $996,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new position in Y-mAbs Therapeutics during the fourth quarter valued at approximately $46,000. Wells Fargo & Company MN increased its position in shares of Y-mAbs Therapeutics by 54.1% during the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock worth $137,000 after purchasing an additional 6,131 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Y-mAbs Therapeutics by 30.7% during the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock worth $139,000 after purchasing an additional 4,163 shares in the last quarter. XTX Topco Ltd increased its position in shares of Y-mAbs Therapeutics by 83.8% during the fourth quarter. XTX Topco Ltd now owns 20,768 shares of the company's stock worth $163,000 after purchasing an additional 9,468 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Y-mAbs Therapeutics by 9.4% during the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock worth $174,000 after purchasing an additional 1,903 shares in the last quarter. Institutional investors and hedge funds own 70.85% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on YMAB shares. Bank of America lowered Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 target price on the stock. in a research note on Tuesday, April 22nd. Morgan Stanley dropped their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a report on Wednesday, March 5th. Wedbush reiterated an "outperform" rating and issued a $18.00 price objective (down previously from $21.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, May 28th. HC Wainwright decreased their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Finally, Oppenheimer decreased their target price on Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating for the company in a research report on Thursday, May 29th. Two analysts have rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $15.60.

Y-mAbs Therapeutics Stock Performance

NASDAQ YMAB opened at $5.27 on Friday. Y-mAbs Therapeutics, Inc. has a twelve month low of $3.55 and a twelve month high of $16.11. The stock has a market cap of $238.65 million, a PE ratio of -9.76 and a beta of 0.52. The firm has a 50-day simple moving average of $4.40 and a 200 day simple moving average of $6.13.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.10. The company had revenue of $20.90 million during the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. Research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

Want to see what other hedge funds are holding YMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.